Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea Biotherapeutics, Inc. (not Spyre Therapeutics, Inc.) on February 24, 2021, regarding events occurring on February 23, 2021. The company is a Delaware corporation with its principal executive offices in Austin, Texas, and its common stock trades on the Nasdaq Global Market under the symbol "AGLE". The company is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the appointment of Sara Brownstein as a Class I director and a member of the Nominating and Governance Committee, effective February 23, 2021.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the details of the new director's appointment and compensation package:
- Annual Retainer: Ms. Brownstein will receive a pro rata portion of the $40,000 annual retainer for director service and a pro rata portion of the $4,000 annual retainer for Nominating and Governance Committee service for the remainder of the year.
- Stock Option Grant: The Board granted an option to purchase 47,200 shares of common stock. The exercise price is equal to the closing sale price on February 23, 2021. The option vests monthly over three years, contingent on continued service.
- Indemnification: The company entered into its standard form of indemnification agreement with Ms. Brownstein.
The filing states there are no family relationships between Ms. Brownstein and other directors or officers, and no undisclosed material interests in transactions.
Investor Verification Checklist
- Verify the closing stock price of AGLE on February 23, 2021, to determine the exercise price of the 47,200 share option grant.
- Review the company's existing compensation policy for non-employee directors to confirm the pro rata calculation methodology.
- Confirm the vesting schedule details (monthly over three years) in the definitive stock option agreement.
- Check subsequent filings for any changes to the Board composition or Ms. Brownstein's committee assignments.